Abstract: The general process of in silico drug discovery includes identification of therapeutic target, cause and mechanisms revealing, generation of small compounds library, docking and scoring, pharmacokinetic studies, and lead compound generation. There are two common types of CADD approaches, structure based drug design (SBDD) and ligand based drug design (LBDD). MedAI has set up an expert team of structure biologists, biophysicists and computational scientists for discovery of new chemical entities.Summary: Computer aided drug design (CADD, or in silico screening) has become a powerful technique in the process of drug development and drug discovery, to facilitate the drug design process thereby minimizing time and costs. References: https://aimed.protheragen.com/cadd-platform.html
Ask the author a question about this poster.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Assessment of Long IVT mRNA Fragments with the Agilent Fragment Analyzer System
Chava Pocernich, Kyle Luttgeharm, and Steve Siembieda
AI & Medicine
Quantitative mechanistic model for amyloid beta and tau protein role in synaptic plasticity
Stepan Lerner, Tatiana Karelina